Arcellx, Inc. (NASDAQ:ACLX) Director Jill Carroll Sells 504,263 Shares

Arcellx, Inc. (NASDAQ:ACLXGet Free Report) Director Jill Carroll sold 504,263 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $70.55, for a total transaction of $35,575,754.65. Following the sale, the director now directly owns 1,479,148 shares in the company, valued at $104,353,891.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Arcellx Price Performance

NASDAQ:ACLX opened at $68.83 on Tuesday. The stock has a market capitalization of $3.63 billion, a PE ratio of -46.82 and a beta of 0.02. The business’s 50-day simple moving average is $64.57 and its 200-day simple moving average is $51.66. Arcellx, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $75.10.

Arcellx (NASDAQ:ACLXGet Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.95. Arcellx had a negative return on equity of 20.96% and a negative net margin of 64.08%. The company had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $20.07 million. During the same quarter in the prior year, the business posted ($0.76) EPS. On average, research analysts expect that Arcellx, Inc. will post -1.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ACLX has been the subject of a number of recent analyst reports. Truist Financial increased their target price on shares of Arcellx from $57.00 to $87.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. HC Wainwright increased their price target on shares of Arcellx from $60.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Barclays increased their price target on shares of Arcellx from $62.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Canaccord Genuity Group increased their price objective on Arcellx from $66.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Finally, Robert W. Baird increased their price objective on Arcellx from $63.00 to $77.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $69.14.

Check Out Our Latest Stock Report on ACLX

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Arcellx by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 2,061,819 shares of the company’s stock worth $114,431,000 after purchasing an additional 23,262 shares in the last quarter. Perceptive Advisors LLC grew its holdings in shares of Arcellx by 14.6% during the 4th quarter. Perceptive Advisors LLC now owns 4,544,809 shares of the company’s stock worth $252,237,000 after purchasing an additional 578,831 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Arcellx by 34.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,260,180 shares of the company’s stock worth $69,941,000 after buying an additional 323,309 shares during the last quarter. Voloridge Investment Management LLC boosted its stake in Arcellx by 128.8% in the fourth quarter. Voloridge Investment Management LLC now owns 235,760 shares of the company’s stock valued at $13,085,000 after buying an additional 132,709 shares in the last quarter. Finally, Voya Investment Management LLC boosted its stake in Arcellx by 42.6% in the fourth quarter. Voya Investment Management LLC now owns 81,472 shares of the company’s stock valued at $4,522,000 after buying an additional 24,320 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

Arcellx Company Profile

(Get Free Report)

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Read More

Insider Buying and Selling by Quarter for Arcellx (NASDAQ:ACLX)

Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.